8
~~
129

	59 a		S. S.			<u>ක</u> ස		40		\$ \$		38 8		29 8	į	ω	රි	ເກ	F-3		-
пр31	arp30	17p28	mp26	arp25	7 <b>p</b> 16	arp14	ç	3	arp12	arp11	arp10	තිය	<b>7</b> 04	arp_1	arp_16	arp_17	arp 24	arp_25	뮸		****************
FIV	CDHLRY	DEH	FLΥ	S R	ΥQΗ	Œ	G aid	אמשממע	ኋ	DGLPSV	EQγ	EKW	QR	AS	AV	AT		₹	Diversity	Diversity	presententententen
31V=38A=40F=40Y, 31	30H=37L=38L=85A=85V	28H=30G		Q., R		m#X	9	195=315=34		11G=13Y=14E=14=K25 Q=25R=30L 11S=12K=12T, 11P=13R	10E=31V=38A=40Y= (166Q)=(166R)	9K=11D=26Y=28H=30G	Q= <b>R</b>	A=S	A=V	A=T	***	X#Z		Equivalence	harmanaeneeneeneeneeneeneeneeneeneeneeneenee
						6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6		o de la company de la comp								***************************************			Total	Total (+) Vs (-)	A STATE OF THE STA
A . *** ::				•				,		V(-)>hetero			Charles con contrate		A(-)>hetero Vhomo>hetero	Ahomo-hetero T(-		K(-)>hetero Rhomo>hetero	Total	Total (homo)	AND THE PARTY OF T
FV77.8	0000	DE69.2	LY70.2		H07150	EE66.2	FR71.6	EVIDO	KK66.5	GV100 LL1000	EY83.3	KW74.2	OR68.3	SS83.36	VV78.8	AA76.6	FI66.7	RR78.8		Total	CANADA CONTRACTOR CONT
#15v #11						Opt		-									F(-)>(+)		Stomach	Total (+) vs (-)	Mercarenteraterarenterarenterarente
			Unetero>		Qhelero>					Vhetero×(-)							Terrarena econocione con terrarena econociona de la constanta		Stomach	Total (homo)	estantian diversal and an extension
FV76.2	201000 1000	DE69.4	LY80.3		HQ830	EK80	GR75.4	27100	TT70.7	LL 100	EY75	KW75.8	RR68 1	SS100	W/71.4	AA67.8	LL60.9	RR71.4		Stomach	Name of the Party
[[+]×[+]				÷				T					4	A(+1×(_), S(-		,,	AKAND TANDAK CONTRACTOR CONTRACTOR		Other	Total (+) vs (-)	Museumestinennesnuesnuesnuesn
Fhetero>homo			Fhetero-homo				Rhetero-homo Shetero (- )-homo	Theres:		Phetero>homa				A, Shomohetero>		***************************************			Other cancers	Total (homo)	weareness and the second secon

Fig. 53

107	8	සි			9	99	တ္တ	88	87		 05	76	66	67	4	333	క్ష	<u>0</u>				-
arp78	arp77	arp74	arp73		arp71	arp70	arp67	arp60	arp58		arp57	arp47	arp40	arp38	1	arn37	arp33	агр32		뮸		diversioners
	목		AG		AEKR	DQR	<u> </u>	YAH	Æ		ADSV	FΥ	Fγ	ALV		PINSY	¥	ΗΥ		Diversity	Diversity	, ;
<b>∀=</b> Υ	N=T	R-N	73A=73G=74R=74N= 77N=77T			edimeraneanuranuranuranuranuranuranuranuranuran			A=E			: F=Y	F=Y			S	H.Z	:: H=Y			Equivalence	***************************************
• • • • •					*** / / / * * *	wassessessessessesses			ede de la compresa del compresa de la compresa del compresa de la compresa del la compresa de la compresa del la compresa de l								*****	,		Total	Total (+) vs (-)	Prognosis
					K(-)>hetero						Shetero (-)>homo			an diploma a propriata a apropria						Total	Total (homo)	Prognosis
VY67.1	TT66.4	LR80	AA66.3	AE72.6	AR63.5,	DD69.4	F168.5	: HS73.7	AE67		AV73.70	FY67,4	FY73.1	LL800		 88 85	NN66,7	9.994H		, ·••	Total	Prognosis
	• • • • • • • • • • • • • • • • • • • •				X:-\V:-\V:-\V:-\V:-\V:-\V:-\V:-\V:-\V:-\V			•••												Stomach	Total (+) vs (-)	Prognosis
		•			K(-)>hetero				e stille e e stille e e e dels e e editits e estilles e estilles e estilles e e											Stomach		Prognosis
0.89AV	TT68.2	AQ1000	AA68.1		FR750	DD72.7	FI72.2	HY68.4	AE71.1	SV72.5	AD72.5,	YY68.9	FY71.6	AV78.8		FS73.4	HH71.4	4468			Stomach	Prognosis
			***************************************								****				.,,		*****		cancers	Other	Total (+) vs (-)	Prognosis
****					A Ehelero>					homo	Shellero (-)				helero-homo	n				Other cancers	Total (homo)	Prognosis

Fig. 54

etero
(-)>(+) R Thomo>h
***************************************
••
Stomach
Total (+) vs (-) Total (homo) Stomach
ì

arp31 FIV	arp30 CGHLR Y	arp28 DEH				arp14 EK	arp13 FGHRS Y	arp12 KT	arp11 DGLPS	arp10 EQY		aip4 QR	arp1 AS	arp16 AV			arp 25 KR	DR Diversit	Diversit v	
31V=38A=40F=4	ILR 30H=37L=38L=8 5A=85V	.,		Q=R		m=x		,	PS 11G=13Y=14E=1 4=K25Q=25R=3 0L 11S=12K=12T, 11P=13R	10E=31V=38A=4 0Y=(166Q)=(166 R)		Q=R	A=S	` A=V	A=T	T. <u>≥</u>	<b>⊼</b> #20	rsit	rsit Equivalence	*****
4 FV80	3 CC100		EL 100		QY100	EE63.5	FR74.20	KK64.2	T 1000	4 EY100			AA90 9O	VV100	AA100	FL100	RR100		Other cancers	
Immunotherapy	no adjuvant therapy H(+)>(-) immunotherapy R(-)>(+)		Chemotherapy 26L(+)>(-)				Immunotherapy Shetero* (- ) homo			Immunotherapy E(+)>(+)								Total	Total (+) vs (-)	
Immunotherapy V (-	Immunotherapy Ri- )>hetero	Immunotherapy Ehetero (-)-homo	Chemotherapy Litelero > (.) homo immunotherapy Litelero (.) ->homo					\$.2.XX	Immunotherapy Vhomo ((-))>hetero	Immunotherapy E(-) >hetero					****			Total	Total (homo)	
Immunotherapy FF			no adjuvant therapy FL(87), immunosherapy FL(61.4)				no adjuvant therapy GH(89.9) Immunotherapy FS(81.9)		no adjuvant therapy DS(83.4)DV/79.6), Immunotherapy DP (84.6)		Immunotherapy KW (86.7)				Immunotherapy AA 71.4				All cases	
Immunotherap	Immunotherap y R(-)>(+)									Immunotherap V E(+) ×(+)								Stomach	Total (+) vs (-)	Effect
Immunotherapy Vi-		Immunotherapy Ehetero (-) >homo	Chemotherapy Lhetera ((-))>hama Immunotherapy Lhetera (-)>homa	**************************************	**************************************	· · · · · · · · · · · · · · · · · · ·	Immunotherapy Hhomo ((-))>hetero		Immunotherapy Vhomo ((-)) >hetero	Immunotherapy E(-) >hetero	Immunotherapy E (+), (homo)>hetero							Stomach	Total (homo)	
		Immunotherapy EH (68.6)	Immunotherapy LY66 7		***************************************						Immunotherapy KW 84.6								Stomach cancer	

## Fig. 56

- ACTIVATOR AND				-		VV69.3	:	W	arp78
Chendherapy IT(58)	Chemotherapy Mi phetero: Chemotherapy Thompyhetero	Chemotherapy N(-)=(+)				NT83.3	X H	Z	arp77
no adjuvant therapy EL (90.9) Chemotherapy AL (96.1) Immunotherapy AE (67.5)	Immunotherapy Ahelero (- )thoma Chemotherapy (- ) Histero	Chemotherapy R(-1>(+)	Immunotherapy AE(679)	Immurotherapy Aneiro (135-homo Immurotherapy Ehelsio homosis)	Chemotherapy El (>(+) Immunotherapy E(+)>(-)	ERIDOO	R: X	AELQR	arp74
Chemotherapy AA (58)	Chemotherapy Ahomo*hetera Chemotherapy Gripherapo	Chemotherapy G(+)>(+)				AG65.6,	73A=73G=74 R=74N=77N= 77T	AG	arp73
no adjuvant therapy ER(917) Chemotherapy AA(778)		no adjuvani therapy K/-y-(+)	nu adjuvant therapy RR(81-8) Immunotherapy ER(73.7)	no adjuvant therapy Ahelero (( ))>homo Ehelero ((-))>homo	no adjuvant therapy K(- lor(+)	KR7880		AEKR	arp71
no adjuvant therapy DQ (86.5)	no adjuvant merepy Dheleio-homo (-)				Chemotherapy R(-)>(+)	RR69.4		DQR	arp70
Chemotherapy II(74.8)	Chemotherapy homowhetera (-) Chemotherapy (1,-) homowhetera		no adjuvant therapy IL(82.8), Chemotherapy FI(63.4), Immunotherapy FL(68)	immunotherapy i(- )>homo, hetero, no adjuvani therapy Lhetero>(-),homo, Chemotherapy L(- )>hetero,homo	Immunotherapy (i-)>(+) Chemotherapy (i-)>(+)	FF72.4		<u> </u>	arp67
			Chemotherapy YY (56.8)		Chemomerapy H (-)>(+)	6 385H		НАҮ	arp60
				213		AA63.5	ARE	ΑE	arp58
no adjuvant therapy SV(100) Immunotherapy AD(83.3)			no adjuvant therapy SV(92.2), Chemotherapy DD(60.3), Immunotherapy AD(70.2)	no adjuvant therapy Shetero ((-))>homo	Chemotherapy A(-)-i+)	AV88 90		ADSV	arp57
Chemotherapy FF(74.5)		***				FY67.3	; F≖Y	 ?	arp47
	Immunotherapy Y (- )>hetero		Immunotherapy FF(57.5)	Imnunotherapy Fhomo-hetero Imnunotherapy Yi J-hetero	(+)-d-1,4 Adesagounum	FY75	Fi-Y	FZ	arp40
	Immunotherspy Al- inherso	Immunotherapy A(-)>/+)		immunotherapy Ai- inhetero	Immunotherapy A(-)>(+) no adjuvant therapy L(+)>(-)	LL 100		ALV	arp38
Immunotherapy NS(69.1)			Chemotherapy I.Y/70-9) Immunotherapy NS(72-5)	Chemotherapy Fi Shele is homo Immunotherapy Whatero (homo)s)	Chemotherapy F>++) no adjuvant the apy L ++>+-) Immunotherapy N(++>+)	F18330	ጥ 8 60	FLNSY	arp37
Immunotherapy HH(87.5)	Immunotherapy Hitomovii )) hetero Immunotherapy Ni Injingnoj Inetero	Immunotherapy N(-)=(+)				HN04.5	Ŧ	Z	arp33
	STORMACT	Siomach		E 0(8)	} 0188	HY64,6	Н=ү	HY	arp32
Stomach cancer	Lessonssanssans	Total (+) vs (-)	All cases	Total (homo)	Total (+) vs (-)	Other cancers	Eguivalence	Diversity	3
Treatment Effect	Heannein chect	Leanneth Chect	- Federica Circo	Frequient Chect	Healthair Chac	Clark Maria	-	-	

		arp26 DEH	288 C. 191	ļ.,.,	arp16 HQY	arp14 EX	arp13 FGHRSY	arp12 KT	*************						arp 25 KR	*	Diversity	
100-110C	CDHLRY   30H=37L=38L   =85A=85V		s ee ks	Q=R		mex.	RSY					 Α=S	 		スポカ	rs#v	rsity Equivalence	
=40F	#38L			,			& ************************************		#14 50# #12T	=38A (5C)	26Y G					Other cancers		Treatment Effect
	erri Ver	Chemotherapy helefol (2)tomo	Chemotherapy F(-)				no adjuvent therapy Rhetero (- >homo Chemotherapy Shetero (-)-homo Immunotherapy Shetero (-) homo		no adjuvant therapy Phetero (-) -humo		no adjuvant therapy Whelero (-) -ngmo					Other cancers	Total (homo)	Treatment Effect
		Chemotherapy EE 100					no adjuvant therapy FR(80). Chemotherapy FR(72). Immunotherapy FS(100)				no adjuvani therapy KWI88.9)	no adjuvant therapy AA(100)				stadje hares	Other cancers	Treatment Effect
	N. 2818 V		***************************************														Cancer in Family	DR
	5 - CP 55 - C	***	<b>**</b> *	***************************************		<b>4</b> 4:		***************************************						FU80 LL 22 90			Melastases	DR
	**** / ***				QQ100, YY6, 30		FT22.6, FF0, GR0, O									advanced cancer)	Total t(ratio of	DR
	* 100 g * 50	***************************************	<b>**</b>									AS73.3 AA44.40		<b>S.</b> ,			Smeking	DR

Fig. 59

reschiese misser		DR DR	arp32	вгр33	arp37	25038	arp40	arp47	arjp57	arp58	arp60	arp67	arp70	arp71	arp73	arp74	arp77	agy78
Diversity		Diversity	¥¥	Ξ	FLNSY	V 14	 ??	ĘŻ	ADSV	Æ	НАҮ	7	Ω	AEKR	ÅG	AELQR	z	₹
Equivalence		h • •	H= <b>Y</b>	I.	F #S	والأوام والماداء والماداء والماداء والماداء والماداء والماداء والماداء	F=7	F:=∀	**************************************	A=E					73A=73G=74 R=74N=77N= 77T	Z	Z=T	
Total (+) vs (-)		Other cancers	Chemotherapy Y(+)>(-) Immunotherapy Y(+)>(-) Chemotherapy H(-)>(-)						Chemotherapy A(-) >(+)							no adjuvani therapy Li-		
Total (homo)	e bomes	: Other cancers	Chematherapy H(-   hatero-homo   mmunutherapy hetero (   )-komo Chematherapy Yhetero homo-(-)   mmunutherapy Yhetero homo-(-)		Chemotherapy Fr (hetero)-homo no adjuvant therapy Shetero (				Chemotherapy A(+)> (hetero),homo (mnunotherapy Shetero) (-)-homo		Chemotherapy His prinateral fromo			no adjuvant therapy Attelero († 1)>homo	<b>ко</b> чко	no adjuvant therapy Ahalero (- )-homo		the factor from
Other cancers			Chemotherapy HY(55.6) Immunotherapy HY(55.6)						no adjurant therapy SV(81-8), Chemotherapy VV(85-7), immunotherapy DS(78-8)		Chemomerapy 35(65.7) Immunotherapy HY(75)	no adjuvani therapy FF35.7. IL78.3		no adjuvant therapy AR/74 9)		no adjuvant therapy(AE81), Chemotherapy (AE84.4)		,
Cancer in Family						***	***************************************											, , ,
Metastases	• ( )	***				· Section of the sect				4								•••
Total t(ratio of	cancer)			HN183 NN980		i de a a debita a al debit a a debita a abbita a abbita a abbita a abbita a abbita a abbita a a debita a a debit									.,,,			
Smoking	*****					to a special section of the section				- Company of the Comp								• * *

Fig. 60

OR	Diversity Diversity	Equivalence	Treatment Effect Total (+) vs (-) Other cancers	Treatment Effect Total (homo) Other cancers		I Treatment Effect Other cancers		Treatment Effect Other cancers	Other cancers Cancer in Family
DR DR	Diversity	Δ=V	Other cancers	Other cancers					
arp86	9	G=V	Chemotherapy G(+)-(-)	Chemotherapy Chomo helesport	Chemic	Chemotherapy VV(90)	therapy VV(90)	therapy VV(90) #	
агр96	THQY			no adjuvant therapy Q; ) helefo-fromo	no adj	no adjuvant therapy HY(100)	uvant therapy HY(100)	uvant the apy HY (100)	want therapy HY(100)
arp98	Œ,	98E=98K=104 A=104S	immunotherapy K(+1×(-)	Inmunotherapy Ehetero (- jehomo Immunotherapy Khelero homoe(-)	lmmu	Iranunoiterapy EK(66.4)	rotherapy EX(66.4)	rollierspy EX(68.4)	rollie/apy EK(68.4)
arp104	AS	A=S	Immunotherapy S(+)>(-)	Immunotherapy Ahetero (- )-homo (immunotherapy Shelero homo>( )	mana	immunotherapy AS(819)	otherapy AS(819)	rotherapy AS(819)	rotherapy AS(819)
arp120	Z.	S=2					#	*	**************************************
arp133	Æ	1331×133R×1 42M=142V	no adjovani therapy RI+JX(-)	no adjuvant therapy Lhetero (-)>homo no adjuvant therapy Rhomo hetero>(-)	no adj	no sduvant therapy RR(69.1)	uvant therapy RR(69 1)	uvant therapy RR(69 1)	want therapy RR(69 I)
arp140	AT								
arp142	&V V	M≈V	no adjuvant therapy V(+)>(-)	no adjuvant therapy Mhetero (-)>homo no adjuvant therapy Vhomo hetero>(-)	no adju	no adjuvent therapy VV(69.1)	wart thezapy VV(69.1)	wint therapy VV(69-1)	wint therapy (VI(SO 1)
arp149	Ą	H=Q						aurourourourourourourourourourourourourou	он о
apr164	FV			•		***************************************	All to al	montonionionionionionionionionionionionionio	anoanoanoanoanoanoanoanoanoanoanoanoanoa
arp 166	Q R	O-B	**************************************			***************************************			
arp 180	. ΓΛ	\ \			no adju	no adjuvant therapy LV(100)	vant therapy LV(100) #	Ì	Ì
arp181	. AT	***************************************							
arp189	RS	R≓S				***************************************			
arp231	PÕ	р Д							
arp233	77	<i>₹</i>	Immunotherapy T(+)>(-)	Immunotherapy Rhesero (- )-homo Immunotherapy hetero forno-(-)	immun	mmurotherapy RT(77.9)	merapy RT(77.9)	itherapy RT(779)	merapy RT(77.9)
v	<b>≜</b>				****				
	survived		****						

		<u></u>		<b>&amp;</b>			85		65	2	2004	<u>چ</u>		***************************************		
app86	app85	app84	app76	аррб9	app65	app57	app 56	арр55	app.36	арр35	app11	app9	app8	OF.		
Αp	EG	S	- PA	프	7	DE E	Æ	ADE	AV	ΥJA	ഉ	FHY	. EV	Unersity		· ·
	16.	18.23		m Z	: 65}=65L			**************************************	A≈V		G#L		8L=8V=9F =11G=11L	,	r.quivarence	
	. / **	V. 4. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.							***************************************					(003)	VS (-)	Prognosis
						•••			***				******	(Otal	(ona) (nomo)	Prognosis
AP66.9	EG68.9	DG65.9	H100	EK68.6	: LL85.7	DD68.5	EE67.5	AA85.7	AA85.7	FF68	GL67.3	FY68.2	LV67.4	(00)		Progrega
	****	****				***	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					****	*******	Stormacn	(-)	Prognoss
	****					,			,			****	**** 6****	SIDITIACIT	(nomo)	Prognoss
PP70.8	GG70.8	GG70.8	N300	E X 66 9 A	: LL85.7	DD76	EE70.8	AA80	AA80	FY76.90	LL77.8	YY85.7	VV77.8	Stornach		Progress
~~							***************************************							cancers	Vs (-)	Prognosis
						, , , ,								cancers	(nomo)	Pragnosis
AP65.9	EG85.9	DG65.9	IM67.70	EK6790	IL64.6	EE64.2	AA67.3	AA100	AA100	LY68.8 LY68.8	9084 9184 90	FY6580	LV64.70	Cancers		Frognos/s
														16101	(+) sv (-)	Effect
				no adjuvant therapy Ehetero-/ J. homo no adjuvant therapy Khetero-/fi omoj		,								1018	(ognon) (go)	Effect
				no adjuvant therapy Ek (81.4)				AD 70			******				, in the	

116 126 126 app87 app96 app170 app178 Overall Progno sis ç More than 3, all 동구중동 Diversity survived Equivalence Total (+) Prognosis (ota) Total (homo) Prognosis MV66.9 KK100 II100 LM70.6 DP9YY(5) Total Programs . (-) Stomach Prognosis Total (+) vs Stomach Total (homo) Prognosis MM70.8 H100 MM75 DP65LL( 5) Progress. Stomach Total (+) Vs (-) Other Prognosis cancers Prognosis Other cancers Fotal (homo) Other cancers MV65.9 KR65.3 Progress Treatment Effect Total (+) Vis (-) Treatment Effect Total (horno) Total Treatment Effect All cases

Fig. 63

app85	арр84	арр76	app69	app65	app57	арр56	арр55	app36	app35	app11	app9	app8	뮻	***************************************
A G	DG	VM.	<b>9</b>		DE	À	(Consecutive	ĄV	FLY	Q	FHY	V.	Diversity	***************************************
		,	Immurothersp y E(+>(+)								Immunotherap y Ht 1×(+)		Siomach	Total (+) vs (-)
		Chemotherapy I(-), (homo inhetaro	no adjuvant therapy Ehetero ((+), homo Immunotherapy E; (fielero i-homo, no adjuvant therapy (thetero-thomo) (+) Immunotherapy (thurno thelero) (+)				Chemoliserapy A; ) (homo) -heliaro	Chemotherapy At Thomo:>hater Chemotherapy Thomo (t >hater			Immunatherapy H(- ),(Itomo)>hetero		Stomach	Total (homo)
		Chemotherapy MV(64)	no adjuvant therapy EK (85.4) Immunotherapy KK (58.3)					Chemotherapy (W/)	Chemotherapy (FF)		Immunotherapy FY(67.1) FF(65)			Stomach cancer
			no adjuvant therapy K(+)>(-)	no adjuvant therapy L (+)>+)	no adjuvant therapy E (+)×(-)	no adjuvant therapy A(+)>()	,			no adjuvant Iherapy Gi+(>r-)	no adjuvant Berapy F(+)>+)		Other cancers	(-) SA (+) /810]
1	***************************************	no adjuvant therapy Vitale o Lizhomo		no adjuvant therapy helerozhono no adjuvant therapy Lhelero homo (-), no adjuvant therapy E(- ) heterozhono no adjuvant therapy lhelerozhono (-)	no adjuvent therapy Chaters, (+>+roms, no adjuvent therapy Ehetens froms>+, )	no adjuvant therapy Aneterory i homo ino adjuvant therapy Eheterory i homo	no adjuvant therapy Dhetero/ J thomo			no adjuvent therapy Ghetero homovi i, no adjuvent therapy Li i heterovhomo	no adjuvant therapy Ehelero homo>(-), no adjuvant therapy Hi (helero>homo	no adjuvant therapy Vhetero ( )-hamo	Cither cancers	Total (homo)
		no adjuvant therapy MV/79)	no adjuvant therapy EK(717)	no sdjiwant therapy IL(100) o	no adjuvent therapy DE (76.8)		no adjuvant merapy DE 76.3)		Chemotherapy (LY)	na adjuvent therapy(GL)	no adjuvant therapy (FY)	no adjuvant therapy (LV)		Other cancers
EE92 1 GG87 60	DD92 1 GG878D	W95 6, H66 70			W96.3 LL89.60					VV95 211.89 60	#	VV952 LL89-5O	malignancy)	Category (rate of
							AE#48 AA10	#					Tree tree tree tree tree tree tree tree	Metastases